Other biomarkers such as tumour mutational burden and tumour infiltrating lymphocytes are now being explored as PD-L1 independent predictive biomarkers for immune responsiveness of the tumour in immunotherapy of TNBC [20]. This evidence concerns the gene CD274 and neoplasm.